PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research
Identifieur interne : 002D55 ( Main/Exploration ); précédent : 002D54; suivant : 002D56PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research
Auteurs : D. Guilloteau [France] ; S. Chalon [France]Source :
- Current pharmaceutical design [ 1381-6128 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Physiopathologie, Tomoscintigraphie émission monophotonique, Tomographie émission positon, Médicament, Protéine transport, Recherche développement, Chimiothérapie, Toxicité, Trouble attention, Hyperactivité, Autisme, Etat dépressif, Dépression, Dopamine, Parkinson maladie, Site action, Mécanisme action, Traitement, Trouble de l'attention avec hyperactivité, Imagerie moléculaire, Transporteur sérotonine.
- Wicri :
- topic : Médicament.
English descriptors
- KwdEn :
- Attention Deficit Disorder with Hyperactivity (diagnostic imaging), Attention Deficit Disorder with Hyperactivity (drug therapy), Attention disorder with hyperactivity, Attentional disorder, Autism, Autistic Disorder (diagnostic imaging), Autistic Disorder (drug therapy), Carrier protein, Chemotherapy, Depression, Depression (diagnostic imaging), Depression (drug therapy), Depressions, Dopamine, Dopamine Plasma Membrane Transport Proteins (analysis), Drug, Drug Design, Humans, Hyperactivity, Mechanism of action, Molecular imaging, Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson disease, Pathophysiology, Positron emission tomography, Positron-Emission Tomography, Research and development, Serotonin Plasma Membrane Transport Proteins (analysis), Serotonin transporter, Single photon emission tomography, Site of action, Tomography, Emission-Computed, Single-Photon, Toxicity, Treatment, Vesicular Monoamine Transport Proteins (analysis).
- MESH :
- chemical , analysis : Dopamine Plasma Membrane Transport Proteins, Serotonin Plasma Membrane Transport Proteins, Vesicular Monoamine Transport Proteins.
- diagnostic imaging : Attention Deficit Disorder with Hyperactivity, Autistic Disorder, Depression, Parkinson Disease.
- drug therapy : Attention Deficit Disorder with Hyperactivity, Autistic Disorder, Depression, Parkinson Disease.
- Drug Design, Humans, Positron-Emission Tomography, Tomography, Emission-Computed, Single-Photon.
Abstract
Membrane and vesicular monoaminergic transporters, responsible for the homeostasis of neurotransmitter pools at nerve endings, are very involved in the physiology and diseases of central nervous system. Recent progresses of cerebral molecular imaging using SPECT and PET methods allow the extend of in vivo exploration of these transporters. For this aim, an increasing number of radiopharmaceuticals labelled with [123I], [99mTc], [11C] or [18F] have been developed such as cocaine derivatives for the DAT, compounds from the diphenyl sulfide family for the SERT, and dihydrotetrabenazine derivatives for the VMAT2. These functional imaging methods can be very useful in several neurological and psychiatric disorders which involve the monoaminergic neurotransmission systems such as Parkinson's disease, ADHD, depression and autism. For example, the DAT is a specific index of the density of dopaminergic endings which progressively degenerate in Parkinson's disease. In vivo exploration of this transporter can therefore be a relevant way (i) to realize an early detection of the loss of dopaminergic neurons, (ii) to assess the progression of the disease, (iii) to validate and improve the efficacy of new therapeutic strategies such as neuroprotection and neuroreparation. In all, the extend of in vivo exploration of monoamine transporters will allow great progress for (1) knowledge of physiopathological mechanisms of brain disorders, (2) early diagnosis of cerebral dysfunctions, allowing early use of new therapies, (3) selection of homogenous classes of subjects for therapeutic assays, (4) objectiveness of drug-molecular target interaction, (5) follow-up of disease evolution and treatment.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000C49
- to stream PascalFrancis, to step Curation: 000785
- to stream PascalFrancis, to step Checkpoint: 000B07
- to stream Main, to step Merge: 003130
- to stream PubMed, to step Corpus: 000F74
- to stream PubMed, to step Curation: 000F34
- to stream PubMed, to step Checkpoint: 000F34
- to stream Ncbi, to step Merge: 000559
- to stream Ncbi, to step Curation: 000559
- to stream Ncbi, to step Checkpoint: 000559
- to stream Main, to step Merge: 002F28
- to stream Main, to step Curation: 002D55
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research</title><author><name sortKey="Guilloteau, D" sort="Guilloteau, D" uniqKey="Guilloteau D" first="D." last="Guilloteau">D. Guilloteau</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Inserm U619, Laboratoire de Biophysique médicale et pharmaceutique, Université François Rabelais</s1><s2>Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Chalon, S" sort="Chalon, S" uniqKey="Chalon S" first="S." last="Chalon">S. Chalon</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Inserm U619, Laboratoire de Biophysique médicale et pharmaceutique, Université François Rabelais</s1><s2>Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0423247</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0423247 INIST</idno><idno type="RBID">Pascal:05-0423247</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C49</idno><idno type="wicri:Area/PascalFrancis/Curation">000785</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000B07</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B07</idno><idno type="wicri:doubleKey">1381-6128:2005:Guilloteau D:pet:and:spect</idno><idno type="wicri:Area/Main/Merge">003130</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16250852</idno><idno type="wicri:Area/PubMed/Corpus">000F74</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F74</idno><idno type="wicri:Area/PubMed/Curation">000F34</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F34</idno><idno type="wicri:Area/PubMed/Checkpoint">000F34</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F34</idno><idno type="wicri:Area/Ncbi/Merge">000559</idno><idno type="wicri:Area/Ncbi/Curation">000559</idno><idno type="wicri:Area/Ncbi/Checkpoint">000559</idno><idno type="wicri:doubleKey">1381-6128:2005:Guilloteau D:pet:and:spect</idno><idno type="wicri:Area/Main/Merge">002F28</idno><idno type="wicri:Area/Main/Curation">002D55</idno><idno type="wicri:Area/Main/Exploration">002D55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research</title><author><name sortKey="Guilloteau, D" sort="Guilloteau, D" uniqKey="Guilloteau D" first="D." last="Guilloteau">D. Guilloteau</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Inserm U619, Laboratoire de Biophysique médicale et pharmaceutique, Université François Rabelais</s1><s2>Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Chalon, S" sort="Chalon, S" uniqKey="Chalon S" first="S." last="Chalon">S. Chalon</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Inserm U619, Laboratoire de Biophysique médicale et pharmaceutique, Université François Rabelais</s1><s2>Tours</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Current pharmaceutical design</title><title level="j" type="abbreviated">Curr. pharm. des.</title><idno type="ISSN">1381-6128</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Current pharmaceutical design</title><title level="j" type="abbreviated">Curr. pharm. des.</title><idno type="ISSN">1381-6128</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Attention Deficit Disorder with Hyperactivity (diagnostic imaging)</term><term>Attention Deficit Disorder with Hyperactivity (drug therapy)</term><term>Attention disorder with hyperactivity</term><term>Attentional disorder</term><term>Autism</term><term>Autistic Disorder (diagnostic imaging)</term><term>Autistic Disorder (drug therapy)</term><term>Carrier protein</term><term>Chemotherapy</term><term>Depression</term><term>Depression (diagnostic imaging)</term><term>Depression (drug therapy)</term><term>Depressions</term><term>Dopamine</term><term>Dopamine Plasma Membrane Transport Proteins (analysis)</term><term>Drug</term><term>Drug Design</term><term>Humans</term><term>Hyperactivity</term><term>Mechanism of action</term><term>Molecular imaging</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Pathophysiology</term><term>Positron emission tomography</term><term>Positron-Emission Tomography</term><term>Research and development</term><term>Serotonin Plasma Membrane Transport Proteins (analysis)</term><term>Serotonin transporter</term><term>Single photon emission tomography</term><term>Site of action</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Toxicity</term><term>Treatment</term><term>Vesicular Monoamine Transport Proteins (analysis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term><term>Serotonin Plasma Membrane Transport Proteins</term><term>Vesicular Monoamine Transport Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Attention Deficit Disorder with Hyperactivity</term><term>Autistic Disorder</term><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Attention Deficit Disorder with Hyperactivity</term><term>Autistic Disorder</term><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term><term>Positron-Emission Tomography</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Physiopathologie</term><term>Tomoscintigraphie émission monophotonique</term><term>Tomographie émission positon</term><term>Médicament</term><term>Protéine transport</term><term>Recherche développement</term><term>Chimiothérapie</term><term>Toxicité</term><term>Trouble attention</term><term>Hyperactivité</term><term>Autisme</term><term>Etat dépressif</term><term>Dépression</term><term>Dopamine</term><term>Parkinson maladie</term><term>Site action</term><term>Mécanisme action</term><term>Traitement</term><term>Trouble de l'attention avec hyperactivité</term><term>Imagerie moléculaire</term><term>Transporteur sérotonine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Membrane and vesicular monoaminergic transporters, responsible for the homeostasis of neurotransmitter pools at nerve endings, are very involved in the physiology and diseases of central nervous system. Recent progresses of cerebral molecular imaging using SPECT and PET methods allow the extend of in vivo exploration of these transporters. For this aim, an increasing number of radiopharmaceuticals labelled with [<sup>123</sup>I], [<sup>99m</sup>Tc], [<sup>11</sup>C] or [<sup>18</sup>F] have been developed such as cocaine derivatives for the DAT, compounds from the diphenyl sulfide family for the SERT, and dihydrotetrabenazine derivatives for the VMAT<sub>2</sub>. These functional imaging methods can be very useful in several neurological and psychiatric disorders which involve the monoaminergic neurotransmission systems such as Parkinson's disease, ADHD, depression and autism. For example, the DAT is a specific index of the density of dopaminergic endings which progressively degenerate in Parkinson's disease. In vivo exploration of this transporter can therefore be a relevant way (i) to realize an early detection of the loss of dopaminergic neurons, (ii) to assess the progression of the disease, (iii) to validate and improve the efficacy of new therapeutic strategies such as neuroprotection and neuroreparation. In all, the extend of in vivo exploration of monoamine transporters will allow great progress for (1) knowledge of physiopathological mechanisms of brain disorders, (2) early diagnosis of cerebral dysfunctions, allowing early use of new therapies, (3) selection of homogenous classes of subjects for therapeutic assays, (4) objectiveness of drug-molecular target interaction, (5) follow-up of disease evolution and treatment.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Centre-Val de Loire</li><li>Région Centre</li></region><settlement><li>Tours</li></settlement></list><tree><country name="France"><region name="Centre-Val de Loire"><name sortKey="Guilloteau, D" sort="Guilloteau, D" uniqKey="Guilloteau D" first="D." last="Guilloteau">D. Guilloteau</name></region><name sortKey="Chalon, S" sort="Chalon, S" uniqKey="Chalon S" first="S." last="Chalon">S. Chalon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:05-0423247
|texte= PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research
}}
| This area was generated with Dilib version V0.6.29. |  |